We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients Product Name:Policresulen CAS No.:9011-02-3 Standard:In-house Standards Price(USD):0.00 Company:Arshine Group Co.,Ltd.
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Payment Terms: T/T,L/C,DP,BANK CONTRACT
Specifications
Name:Policresulen
CAS: 9011-02-3
Specification:EP/USP
top quality,competitive price
Uses
Antiseptic, disinfectant, bleeding medication. First by the German one hundred grams Dayton pharmaceutical research and development, as gynecological external use, primarily for the treatment of cervical erosion, cervicitis, 36% of the preparation of a 50% solution of the original drug solution. Policresulen is a topical hemostatic and fungicide, has a strong role in the killing of pathogens, mainly used in clinical gynecology, surgery and dermatology, has the advantage that no damage to normal tissues.
Identification
Positive reaction
Max absorption at 281+2nm
Tests
Dimer
Not less than 2.0%
M4
Not more than 17.0%
M6
Not more than 7.0%
M4,6
Not more than 1.5%
Absorbance
0.4~0.8
Relative density
1.1~1.3
Barium
To match with reference standard
Residue on Ignition
Not more than 0.2%
Heavy metals
To match with reference standard
Assay
It contains not less than 45.0% and not more than the equivalent of 55.0% of Policresulen
Ten years of qualification
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
